Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Adaptive Biotechnologies Corporation is a commercial-stage company that has developed an immune medicine platform to diagnose and treat diseases. Their main offerings include an immunosequencing platform and the clonoSEQ diagnostic test for monitoring cancer cells, serving life sciences research, clinical diagnostics, and drug discovery. The company holds a significant position in leveraging immune system data for medical advancements.
AI-generated summary. Not investment advice.